Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,237,304 papers from all fields of science
Search
Sign In
Create Free Account
NSC-6396
Known as:
NSC 6396
, NSC6396
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Thiotepa
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1976
Highly Cited
1976
Intrathecal n, n′, n′‐triethylenethiophosphoramide [thio‐tepa (NSC 6396)] in the treatment of malignant meningeal disease. Phase I‐II study
P. Gutin
,
H. Weiss
,
P. Wiernik
,
M. Walker
Cancer
1976
Corpus ID: 21649433
N, N′, N″‐Triethylenethiophosphoramide [Thio‐TEPA (NSC 6396)] is the third drug to be evaluated for the treatment of meningeal…
Expand
1968
1968
Comparison of a combination of 5-fluorouracil (NSC-19893), mitomycin C (NSC-26980), triethylenethiophosphoramide (NSC-6396), and fluoxymesterone (NSC-12165) with 5-fluorouracil alone in patients with…
J. Horton
,
K. Olson
,
T. Cunningham
,
J. Sullivan
Cancer chemotherapy reports
1968
Corpus ID: 38498104
1964
1964
DISTRIBUTION OF C14-LABELED THIOTEPA (NSC-6396) AND ITS METABOLITES IN NORMAL AND TUMOR-BEARING RATS.
Ruddon Rw
,
Mellett Lb
1964
Corpus ID: 88984243
1964
1964
EFFECTS OF PERFUSION WITH THIOTEPA (NSC-6396) ON CARCINOMA VX2 IN HIND LEGS OF RABBITS.
Knoepp Lf
,
Letson Wm
,
Danna Sj
,
Moore Jw
1964
Corpus ID: 77128863
1964
1964
DISTRIBUTION OF C14-LABELED THIOTEPA (NSC-6396) AND ITS METABOLITES IN NORMAL AND TUMOR-BEARING RATS.
R. W. Ruddon
,
L. Mellett
Cancer chemotherapy reports
1964
Corpus ID: 33068279
1964
1964
EFFECTS OF PERFUSION WITH THIOTEPA (NSC-6396) ON CARCINOMA VX2 IN HIND LEGS OF RABBITS.
L. Knoepp
,
W. M. Letson
,
S. Danna
,
J. W. Moore
Cancer chemotherapy reports
1964
Corpus ID: 41195261
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE